CP 2

Drug Profile

CP 2

Alternative Names: CP-2

Latest Information Update: 22 Jul 2016

Price : $50

At a glance

  • Originator AfaSci
  • Developer AfaSci; Kansas State University; University of California, Davis
  • Class Antidementias; Pyrones; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Alzheimer's disease; Diabetes mellitus

Highest Development Phases

  • Preclinical Alzheimer's disease; Diabetes mellitus

Most Recent Events

  • 22 Jul 2016 Preclinical trials in Diabetes mellitus in USA (PO)
  • 22 Jul 2016 Preclinical trials in Alzheimer's disease in USA (PO)
  • 22 Jul 2016 CP 2 is available for licensing as of 22 Jul 2016. http://www.afasci.com/index.php/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top